Invitrogen™ CD335 (NKp46) Monoclonal Antibody (29A1.4), PE, eBioscience™, Invitrogen™

Beskrivelse

Description: The monoclonal antibody 29A1.4 recognizes mouse NKp46, also known as CD335. CD335, a member of the natural cytotoxicity receptor (NCR) family, is a glycoprotein with 2 Ig-like domains and a short cytoplasmic tail. Expression of CD335 is uniquely found on NK cells (including immature NK cells, defined as DX5- CD3-, and thereby allowing discrimination between NKT cells and NK cells (NKp46+, CD3-). Furthermore, unlike many of the NK markers which also stain NKT cells, staining with 29A1.4 is not strain specific. Staining has been shown on C57Bl/6, SJL, CBA/CA and BALB/C strains. NKp46 has been shown to play a role in NK cell-mediated lysis of several tumor cells and pathogen-infected cell lines. The 29A1.4 monoclonal antibody has been shown to activate NK cells in vitro. The 29A1.4 monoclonal antibody does not deplete NK cells in vivo. Applications Reported: This 29A1.4 antibody has been reported for use in flow cytometric analysis. Applications Tested: This 29A1.4 antibody has been tested by flow cytometric analysis or mouse splenocytes. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

CD335, also known as NKp46 or NCR1, is a member of the natural cytotoxicity receptor family, which includes NKp30 and NKp44. This type I transmembrane glycoprotein is expressed on NK cells and plays a crucial role in activating and expanding resting NK cells through interactions with dendritic cells. CD335 enhances the ability of NK cells to eliminate tumor and virus-infected cells, such as those infected by influenza. CD335 consists of two Ig-like domains and is related to leukocyte immunoglobulin-like receptors (LIR) and killer inhibitory receptors (KIR). It contributes to the increased efficiency of activated NK cells in mediating tumor cell lysis. Additionally, CD335 interacts with pancreatic beta cells during the development of type 1 diabetes, highlighting its involvement in both immune defense and autoimmune processes.